Single and multivariate associations of MSR1, ELAC2, and RNASEL with prostate cancer in an ethnic diverse cohort of men

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 2, 2010, Pages 588-599

  Beuten, Joke ^a   Gelfond, Jonathan A L ^b   Franke, Jennifer L ^a   Shook, Stacey ^a   Johnson Pais, Teresa L ^a   Thompson, Ian M ^a   Leach, Robin J ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER RISK; CAUCASIAN; CHROMOSOME 17P; CHROMOSOME 8P; CONTROLLED STUDY; ELAC2 GENE; ETHNIC DIFFERENCE; FAMILY HISTORY; GENETIC ASSOCIATION; GENETIC LINKAGE; GENOTYPE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; MSR1 GENE; PRIORITY JOURNAL; PROSTATE CANCER; RNASEL GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

AFRICAN AMERICANS; AGED; CASE-CONTROL STUDIES; ENDORIBONUCLEASES; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HISPANIC AMERICANS; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; SCAVENGER RECEPTORS, CLASS A;

EID: 76149125153     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0864     Document Type: Article

References (53)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000;343:78-85.
3. Hemminki K, Ji J, Forsti A, Sundquist J, Lenner P. Concordance of survival in family members with prostate cancer. J Clin Oncol 2008; 26:1705-9.
4. Ostrander EA, Stanford JL. Genetics of prostate cancer: too many loci, too few genes. Am J Hum Genet 2000;67:1367-75.
5. Ostrander EA, Markianos K, Stanford JL. Finding prostate cancer susceptibility genes. Annu Rev Genomics Hum Genet 2004;5: 151-75.
6. Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004;13 Spec No 1:R103-21.
7. Ghadirian P, Howe GR, Hislop TG, Maisonneuve P. Family history of prostate cancer: a multi-center case-control study in Canada. Int J Cancer 1997;70:679-81.
8. Stanford JL, Ostrander EA. Familial prostate cancer. Epidemiol Rev 2001;23:19-23.
9. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate 1990;17:337-47.
10. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A 1992;89:3367-71.
11. Xu J, Dimitrov L, Chang BL, et al. A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet 2005;77:219-29.
12. Simard J, Dumont M, Labuda D, et al. Prostate cancer susceptibility genes: lessons learned and challenges posed. Endocr Relat Cancer 2003;10:225-59.
13. Tavtigian SV, Simard J, Teng DH, et al. A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet 2001;27: 172-80.
14. Minagawa A, Takaku H, Takagi M, Nashimoto M. The missense mutations in the candidate prostate cancer gene ELAC2 do not alter enzymatic properties of its product. Cancer Lett 2005;222:211-5.
15. Camp NJ, Tavtigian SV. Meta-analysis of associations of the Ser217-Leu and Ala541Thr variants in ELAC2 (HPC2) and prostate cancer. Am J Hum Genet 2002;71:1475-8.
16. Noonan-Wheeler FC, Wu W, Roehl KA, et al. Association of hereditary prostate cancer gene polymorphic variants with sporadic aggressive prostate carcinoma. Prostate 2006;66:49-56.
17. Stanford JL, Sabacan LP, Noonan EA, et al. Association of HPC2/ ELAC2 polymorphisms with risk of prostate cancer in a population-based study. Cancer Epidemiol Biomarkers Prev 2003;12: 876-81.
18. Rennert H, Zeigler-Johnson CM, Addya K, et al. Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men. Cancer Epidemiol Biomarkers Prev 2005;14:949-57.
19. Hassel BA, Zhou A, Sotomayor C, Maran A, Silverman RH. A dominant negative mutant of 2-5A-dependent RNase suppresses antiproliferative and antiviral effects of interferon. EMBO J 1993;12: 3297-304.
20. Carpten J, Nupponen N, Isaacs S, et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 2002;30:181-4.
21. Casey G, Neville PJ, Plummer SJ, et al. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 2002; 32:581-3.
22. Li H, Tai BC. RNASEL gene polymorphisms and the risk of prostate cancer: a meta-analysis. Clin Cancer Res 2006;12:5713-9.
23. Shook SJ, Beuten J, Torkko KC, et al. Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans. Clin Cancer Res 2007;13:5959-64.
24. Emi M, Asaoka H, Matsumoto A, et al. Structure, organization, and chromosomal mapping of the human macrophage scavenger receptor gene. J Biol Chem 1993;268:2120-5.
25. Xu J, Zheng SL, Hawkins GA, et al. Linkage and association studies of prostate cancer susceptibility: evidence for linkage at 8p22-23. Am J Hum Genet 2001;69:341-50.
26. Oba K, Matsuyama H, Yoshihiro S, et al. Two putative tumor suppressor genes on chromosome arm 8p may play different roles in prostate cancer. Cancer Genet Cytogenet 2001;124:20-6.
27. Sun J, Liu W, Adams TS, et al. DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. Prostate 2007;67:692-700.
28. Dong JT. Chromosomal deletions and tumor suppressor genes in prostate cancer. Cancer Metastasis Rev 2001;20:173-93.
29. Chang BL, Liu W, Sun J, et al. Integration of somatic deletion analysis of prostate cancers and germline linkage analysis of prostate cancer families reveals two small consensus regions for prostate cancer genes at 8p. Cancer Res 2007;67:4098-103.
30. Xu J, Zheng SL, Komiya A, et al. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 2002;32:321-5.
31. Sun J, Hsu FC, Turner AR, et al. Meta-analysis of association of rare mutations and common sequence variants in the MSR1 gene and prostate cancer risk. Prostate 2006;66:728-37.
32. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-5.
33. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 2003;100:9440-5.
34. French B, Lumley T, Monks SA, et al. Simple estimates of haplotype relative risks in case-control data. Genet Epidemiol 2006;30:485-94.
35. Chen YC, Giovannucci E, Kraft P, Hunter DJ. Association between genetic polymorphisms of macrophage scavenger receptor 1 gene and risk of prostate cancer in the health professionals follow-up study. Cancer Epidemiol Biomarkers Prev 2008;17:1001-3.
36. Hope Q, Bullock S, Evans C, et al. Macrophage scavenger receptor 1 999C>T (R293X) mutation and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2005;14:397-402.
37. Murabito JM, Rosenberg CL, Finger D, et al. A genome-wide association study of breast and prostate cancer in the NHLBI's Framingham Heart Study. BMC Med Genet 2007;8 Suppl 1:S6.
38. Hsing AW, Sakoda LC, Chen J, et al. MSR1 variants and the risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China. Carcinogenesis 2007;28:2530-6.
39. Klein EA, Silverman R. Inflammation, infection, and prostate cancer. Curr Opin Urol 2008;18:315-9.
40. Yeager M, Orr N, Hayes RB, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24.Nat Genet 2007;39:645-9.
41. Thomas G, Jacobs KB, Yeager M, et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008; 40:310-5.
42. Chen YC, Giovannucci E, Kraft P, Hunter DJ. Sequence variants of elaC homolog 2 (Escherichia coli) (ELAC2) gene and susceptibility to prostate cancer in the Health Professionals Follow-Up Study. Carcinogenesis 2008;29:999-1004.
43. Takahashi H, Lu W, Watanabe M, et al. Ser217Leu polymorphism of the HPC2/ELAC2 gene associated with prostatic cancer risk in Japanese men. Int J Cancer 2003;107:224-8.
44. Yokomizo A, Koga H, Kinukawa N, et al. HPC2/ELAC2 polymorphism associated with Japanese sporadic prostate cancer. Prostate 2004;61:248-52.
45. Robbins CM, Hernandez W, Ahaghotu C, et al. Association of HPC2/ ELAC2 and RNASEL non-synonymous variants with prostate cancer risk in AfricanAmerican familial and sporadic cases.Prostate 2008;68:1790-7.
46. Dong B, Kim S, Hong S, et al. An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors. Proc Natl Acad Sci U S A 2007;104:1655-60.
47. Urisman A, Molinaro RJ, Fischer N, et al. Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog 2006;2:e25.
48. Silverman RH. Viral encounters with 2′5′-oligoadenylate synthetase and RNase L during the interferon antiviral response. J Virol 2007;81: 12720-9.
49. Roemeling S, Roobol MJ, de Vries SH, Gosselaar C, Van der Kwast TH, Schröder FH. Prevalence, treatment modalities and prognosis of familial prostate cancer in a screened population. J Urol 2006;175: 1332-6.
50. Noe M,Schroy P,DemierreMF, Babayan R,GellerAC. Increased cancer risk for individuals with a family history of prostate cancer, colorectal cancer, and melanoma and their associated screening recommendations and practices. Cancer Causes Control 2008;19:1-12.
51. Stone SN, Hoffman RM, Tollestrup K, Stidley CA, Witter JL, Gilliland FD. Family history, Hispanic ethnicity, and prostate cancer risk. Ethn Dis 2003;13:233-9.
52. Hayes RB, Liff JM, Pottern LM, et al. Prostate cancer risk in U.S. blacks and whites with a family history of cancer. Int J Cancer 1995;60:361-4.
53. Cunningham GR, Ashton CM, Annegers JF, Souchek J, Kilma M, Miles B. Familial aggregation of prostate cancer in African-Americans and white Americans. Prostate 2003;56:256-62.